A Phase 1 interventional study of Darolutamide (BAY1841788) and Enzalutamide in Cerebrovascular Circulation, sponsored by Bayer. Completed at 1 site in United Kingdom. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-10-30.
Sponsored by Bayer · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The current study would investigate the effects of a single dose of darolutamide and enzalutamide compared with placebo and compared to each other on human brain blood flow using arterial spin labeling magnetic resonance imaging (ASL-MRI), a non-invasive MRI technique. The change in cerebral blood flow was an indirect measure of brain penetration.
The risk of drug-associated CNS-related adverse events was likely to be correlated with the concentration of the drug in the brain. In contrast to enzalutamide, preclinical studies of darolutamide indicate that its brain penetration was much lower.
The aim of this study was to determine whether there was a difference between darolutamide and enzalutamide compared to placebo in cerebral blood flow and thus in brain penetration.
The primary objective was to investigate drug-induced changes in grey matter cerebral blood flow during single-dose treatment with darolutamide or enzalutamide as compared to placebo using voxel-wise quantification of the grey matter for the entire brain.
The secondary objective was to investigate drug-induced changes in regional cerebral blood flow in brain areas related to cognitive function after single-dose treatment.
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Healthy male participants receive drugs in order Enzalutamide, Placebo and Darolutamide.
Drug: Darolutamide (BAY1841788) · Drug: Enzalutamide · Other: Placebo
Healthy male participants receive drugs in order Darolutamide, Enzalutamide and Placebo.
Drug: Darolutamide (BAY1841788) · Drug: Enzalutamide · Other: Placebo
Healthy male participants receive drugs in order Placebo, Darolutamide and Enzalutamide.
Drug: Darolutamide (BAY1841788) · Drug: Enzalutamide · Other: Placebo
Healthy male participants receive drugs in order Darolutamide, Placebo and Enzalutamide.
Drug: Darolutamide (BAY1841788) · Drug: Enzalutamide · Other: Placebo
Healthy male participants receive drugs in order Enzalutamide, Darolutamide and Placebo.
Drug: Darolutamide (BAY1841788) · Drug: Enzalutamide · Other: Placebo
Healthy male participants receive drugs in order Placebo, Enzalutamide and Darolutamide.
Drug: Darolutamide (BAY1841788) · Drug: Enzalutamide · Other: Placebo
300 mg tablet darolutamide, once orally
Also known as: Darolutamide: ODM-201
4 x 40 mg capsules, once orally
Also known as: MDV3100
4 placebo tablets, once orally
Also known as: Darolutamide-matching placebo
Change in grey-matter cerebral blood flow of enzalutamide as compared to placebo
Obtained by comparing whole brain grey matter quantitative voxel-by-voxel maps of cerebral blood flow/ perfusion (mL per 100g tissue per min) of enzalutamide to placebo. Measured in grey matter voxels with arterial spin labeling magnetic resonance imaging (ASL-MRI).
Time frame: At 4 hours after drug
Change in grey-matter cerebral blood flow of darolutamide as compared to placebo
Obtained by comparing whole brain grey matter quantitative voxel-by-voxel maps of cerebral blood flow/ perfusion (mL per 100g tissue per min) of darolutamide to placebo. Measured in grey matter voxels with ASL-MRI.
Time frame: At 4 hours after drug
Change in grey-matter cerebral blood flow of enzalutamide as compared to darolutamide
Obtained by comparing whole brain grey matter quantitative voxel-by-voxel maps of cerebral blood flow/ perfusion (mL per 100g tissue per min) of enzalutamide to darolutamide. Measured in grey matter voxels with ASL-MRI.
Time frame: At 4 hours after drug
Change in mean regional grey-matter cerebral blood flow in brain areas related to cognitive function during treatment of enzalutamide as compared to placebo
Brain areas related to cognitive function comprise hippocampus and frontal cortex. Cerebral blood flow measured with ASL-MRI.
Time frame: At 4 hours after drug
Change in mean regional grey-matter cerebral blood flow in brain areas related to cognitive function during treatment of darolutamide as compared to placebo
Brain areas related to cognitive function comprise hippocampus and frontal cortex. Cerebral blood flow measured with ASL-MRI.
Time frame: At 4 hours after drug
Change in mean regional grey-matter cerebral blood flow in brain areas related to cognitive function during treatment of enzalutamide as compared to darolutamide
Brain areas related to cognitive function comprise hippocampus and frontal cortex. Cerebral blood flow measured with ASL-MRI.
Time frame: At 4 hours after drug
Ran from Oct 2018 to primary completion in Oct 2019, 11 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Darolutamide · Enzalutamide